Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Ng, Lui ^a   Wan, Timothy Ming Hun ^a   Lam, Colin Siu Chi ^a   Chow, Ariel Ka Man ^a   Wong, Sunny Kit Man ^a   Man, Johnny Hon Wai ^a   Li, Hung Sing ^a   Cheng, Nathan Shiu Man ^a   Pak, Ryan Chung Hei ^a   Cheung, Alvin Ho Kwan ^a   Yau, Thomas Chung Cheung ^a   Lo, Oswens Siu Hung ^a   Foo, Dominic Chi Chung ^a   Poon, Jensen Tung Chung ^a   Poon, Ronnie Tung Ping ^a   Pang, Roberta Wen Chi ^a   Law, Wai Lun ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; TUMOR MARKER;

AGED; ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; CANCER SURGERY; CELL MIGRATION ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; BLOOD; COLORECTAL NEOPLASMS; COMPLICATION; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

GASTROPODA;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEOPLASM METASTASIS; OSTEOPONTIN; POSTOPERATIVE PERIOD;

EID: 84930617546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126219     Document Type: Article

References (43)

1. Shike M, Winawer SJ, Greenwald PH, Bloch A, Hill MJ, Swaroop SV. Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ. 1990; 68(3):377-85. Epub 1990/01/01. PMID: 2203551; PubMed Central PMCID: PMC2393072.
2. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012; 5(1):19-27. Epub 2012/05/11. PMID: 22574233; PubMed Central PMCID: PMC3348713.
3. Lin JS, Webber EM, Beil TL, Goddard KA, Whitlock EP. 2012. Epub 2012/03/30. NBK91369 [bookaccession]. 22457883.
4. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007; 16(10):1935-53. Epub 2007/10/13. doi: 10.1158/1055-9965.EPI-06-0994 PMID: 17932341.
5. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix biology: journal of the International Society for Matrix Biology. 2000; 19(7):615-22. Epub 2000/12/05. PMID: 11102750.
6. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001; 280(2):460-5. Epub 2001/02/13. doi: 10.1006/bbrc.2000.4146S0006-291X(00)94146-9 [pii]. PMID: 11162539.
7. Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, Tenen DG. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 1988; 48(20):5770-4. Epub 1988/10/15. PMID: 3167835.
8. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res. 1989; 9(5):1291-9. Epub 1989/09/01. PMID: 2686530.
9. Shiraga H, Min W, VanDusen WJ, Clayman MD, Miner D, Terrell CH, et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci U S A. 1992; 89(1):426-30. Epub 1992/01/01. PMID: 1729712; PubMed Central PMCID: PMC48250.
10. Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16 (6):1087-97. Epub 2007/06/06. 16/6/1087 [pii] doi: 10.1158/1055-9965.EPI-06-1008 PMID: 17548669.
11. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, et al. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14 (22):7470-80. Epub 2008/11/18. 14/22/7470 [pii] doi: 10.1158/1078-0432.CCR-08-0870 PMID: 19010864.
12. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011; 5(2):111-22. Epub 2011/04/26. doi: 10.1007/s12079-011-0130-6 PMID: 21516514; PubMed Central PMCID: PMC3088790.
13. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. British journal of cancer. 2010; 103(6):861-9. Epub 2010/09/09. 6605834 [pii] doi: 10.1038/sj.bjc.6605834 PMID: 20823889; PubMed Central PMCID: PMC2966627.
14. Li J, Yang GZ, Zhu ZM, Zhou ZY, Li L. Osteopontin is overexpressed in colorectal carcinoma and is correlated with P53 by immunohistochemistry. Experimental and therapeutic medicine. 2012; 3(4):621-4. Epub 2012/09/13. doi: 10.3892/etm.2012.465 PMID: 22969940; PubMed Central PMCID: PMC3438587.
15. Mole DJ, O'Neill C, Hamilton P, Olabi B, Robinson V, Williams L, et al. Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases. British journal of cancer. 2011; 104(6):1007-12. Epub 2011/02/24. doi: 10.1038/bjc.2011.33 PMID: 21343932; PubMed Central PMCID: PMC3065273.
16. Likui W, Hong W, Shuwen Z, Yuangang Y, Yan W. The potential of osteopontin as a therapeutic target for human colorectal cancer. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2011; 15(4):652-9. Epub 2011/02/15. doi: 10.1007/s11605-011-1445-6 PMID: 21318445.
17. Likui W, Hong W, Shuwen Z. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2010; 14(1):74-81. Epub 2009/09/19. doi: 10.1007/s11605-009-1035-z PMID: 19763701.
18. Nitsche U, Rosenberg R, Balmert A, Schuster T, Slotta-Huspenina J, Herrmann P, et al. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Annals of surgery. 2012; 256(5):763-71; discussion 71. Epub 2012/10/26. doi: 10.1097/SLA.0b013e318272de87 PMID: 23095620.
19. Abajo A, Bitarte N, Zarate R, Boni V, Lopez I, Gonzalez-Huarriz M, et al. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J Gastroenterol. 2012; 18(7):637-45. Epub 2012/03/01. doi: 10.3748/wjg.v18.i7.637 PMID: 22363134; PubMed Central PMCID: PMC3281220.
20. Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y, et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer. 2013; 132(2):276-87. Epub 2012/06/13. doi: 10.1002/ijc.27670 PMID: 22689289.
21. Wang Y, Shi J, Chai K, Ying X, Zhou BP. The Role of Snail in EMT and Tumorigenesis. Curr Cancer Drug Targets. 2013; 13(9):963-72. Epub 2013/10/31. CCDT-EPUB-57089 [pii]. PMID: 24168186; PubMed Central PMCID: PMC4004763.
22. Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour Biol. 2013; 34(5):2497-506. Epub 2013/07/23. doi: 10.1007/s13277-013-1002-x PMID: 23873099.
23. Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014; 35(8):7335-42. Epub 2014/06/02. doi: 10.1007/s13277-014-2163-y PMID: 24880591.
24. Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clinical colorectal cancer. 2003; 2(4):246-51. Epub 2003/03/07. doi: 10.3816/CCC.2003.n.006 PMID: 12620146.
25. Steller EJ, Raats DA, Koster J, Rutten B, Govaert KM, Emmink BL, et al. PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia. 2013; 15(2):204-17. Epub 2013/02/27. PMID: 23441134; PubMed Central PMCID: PMC3579322.
26. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer cell. 2012; 22(5):571-84. Epub 2012/11/17. doi: 10.1016/j.ccr.2012.08.013 PMID: 23153532; PubMed Central PMCID: PMC3512565.
27. Voorneveld PW, Kodach LL, Jacobs RJ, Liv N, Zonnevylle AC, Hoogenboom JP, et al. Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology. 2014; 147(1):196-208 e13. Epub 2014/04/08. doi: 10.1053/j.gastro.2014.03.052 PMID: 24704720.
28. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006; 17(6):463-74. Epub 2006/11/23. S1359-6101(06)00059-1 [pii] doi: 10.1016/j.cytogfr.2006.09.010 PMID: 17113338.
29. El-Tanani M, Barraclough R, Wilkinson MC, Rudland PS. Metastasis-inducing dna regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res. 2001; 61 (14):5619-29. Epub 2001/07/17. PMID: 11454716.
30. Ng L, Poon RT, Pang R. Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cellular and molecular life sciences: CMLS. 2013. Epub 2013/02/02. doi: 10.1007/s00018-013-1266-8 PMID: 23370778.
31. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007; 56(6):782-9. Epub 2006/12/07. doi: 10.1136/gut.2006.109868 PMID: 17148500; PubMed Central PMCID: PMC1954839.
32. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, et al. Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology. 2005; 68(2-3):285-92. Epub 2005/07/15. doi: 10.1159/000086961 PMID: 16015046.
33. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. Journal of cancer research and clinical oncology. 2007; 133(9):643-52. Epub 2007/05/05. doi: 10.1007/s00432-007-0215-z PMID: 17479289.
34. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer. 2002; 95 (3):506-12. Epub 2002/09/05. doi: 10.1002/cncr.10709 PMID: 12209742.
35. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical cancer research: an official journal of the American Association for Cancer Research. 1997; 3 (4):605-11. Epub 1997/04/01. PMID: 9815727.
36. Zhou C, Zhou HJ, Zhang XF, Lou LL, Ye QH, Zheng Y, et al. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma. Ann Surg Oncol. 2013; 20(3):929-37. Epub 2012/12/04. doi: 10.1245/s10434-012-2749-9 PMID: 23203407.
37. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr., et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(29):4771-6. Epub 2008/09/10. doi: 10.1200/JCO.2008.17.0662 PMID: 18779603; PubMed Central PMCID: PMC2653139.
38. Irby RB, McCarthy SM, Yeatman TJ. Osteopontin regulates multiple functions contributing to human colon cancer development and progression. Clinical & experimental metastasis. 2004; 21(6):515-23. Epub 2005/02/01. PMID: 15679049.
39. Li Y, Galileo DS. Soluble L1CAM promotes breast cancer cell adhesion and migration in vitro, but not invasion. Cancer cell international. 2010; 10:34. Epub 2010/09/16. doi: 10.1186/1475-2867-10-34 PMID: 20840789; PubMed Central PMCID: PMC2949617.
40. Andre F, Janssens B, Bruyneel E, van Roy F, Gespach C, Mareel M, et al. Alpha-catenin is required for IGF-I-induced cellular migration but not invasion in human colonic cancer cells. Oncogene. 2004; 23 (6):1177-86. Epub 2004/02/13. doi: 10.1038/sj.onc.1207238 PMID: 14961074.
41. Huang J, Pan C, Hu H, Zheng S, Ding L. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PloS one. 2012; 7(10):e47901. Epub 2012/11/01. doi: 10.1371/journal.pone.0047901 PMID: 23112867; PubMed Central PMCID: PMC3480452.
42. Dai J, Li B, Shi J, Peng L, Zhang D, Qian W, et al. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer immunology, immunotherapy: CII. 2010; 59(3):355-66. Epub 2009/08/20. doi: 10.1007/s00262-009-0754-z PMID: 19690854.
43. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(6):936-41. Epub 2010/01/21. JCO.2009.25.5711 [pii] doi: 10.1200/JCO.2009.25.5711 PMID: 20085934; PubMed Central PMCID: PMC2834433.